NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies Inc. (Nasdaq:TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today announced the appointment of Jonathan Eckard, Ph.D., as the Company’s Chief Scientific Affairs Officer.
Dr. Eckard brings more than two decades of combined experience in the financial and biotechnology sectors to the company. Before joining Tyme, he was Chief Business and Strategy Officer at oncology-focused Sellas Life Sciences. Previously, Dr. Eckard was a senior biotechnology equity research analyst at Barclays Capital Markets in addition to similar roles at Citi, Leerink Swann and HSBC. As a research analyst, he received accolades including Institutional Investor's "Best up-and-comer" and "Rising Star," and is recognized for his knowledge of oncology therapeutics. Before his career in financial services, Dr. Eckard conducted cancer research and taught at the NYU School of Medicine, where he earned his Ph.D. in Toxicology and Carcinogenesis.
“We are thrilled to have Jonathan join our team, bringing with him an in-depth understanding of our technology as well as strong investor relationships,” said Steve Hoffman, CEO of Tyme. “We are approaching cancer in a very new way and Jonathan will play a valuable role in both the business and communication of our science.”
“Tyme’s technology uniquely interrupts the biological circuitry of tumor cells and represents a novel approach that appears to have broad applicability in cancer,” said Dr. Eckard. “I am excited to be part of SM-88’s advancement towards approval and trying to significantly improve the lives of cancer patients.”
About Tyme
Tyme Inc. is a clinical-stage biopharmaceutical company focused on development and commercialization of highly targeted cancer therapeutics with a broad range of oncology indications. Its lead investigational candidate, SM-88, is a novel first-in-class therapy that is designed to use cancer’s unusual metabolism to selectively break down the cellular defenses of tumors, leading to tumor cell death. Through clinical trials and expanded access programs, SM-88 has been used in over 84 individuals and shown a clinical response in thirteen cancer types. In its first-in-human trial for end-stage, metastatic cancer patients, SM-88 treatment resulted in a median overall survival of 26 months, with 32% of patients alive at the end of the three-year evaluation period without any drug-related serious adverse events. The Company is currently conducting a Phase II trial in prostate cancer in addition to ongoing collaborations with the Mayo Clinic, Mount Sinai and other institutions. For more information, visit our website: www.tymeinc.com.